Iconovo (OM:ICO) - Stock Price, News & Analysis

ICO Stock Overview

Develops and licenses inhalation medications in Sweden. More details

ICO fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 39.4% below our estimate of its fair value

Revenue is forecast to grow 48.46% per year

Trading at good value compared to peers and industry

Risk Analysis

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 1.8% per year for the next 3 years

Does not have a meaningful market cap (SEK82M)

Shareholders have been diluted in the past year

+ 3 more risks

Iconovo AB (publ) Competitors

Q-linea

OM:QLINEA

SEK 131.8m

ScandiDos

OM:SDOS

SEK 92.9m

Odinwell

NGM:ODIN

SEK 59.9m

Glycorex Transplantation

NGM:GTAB B

SEK 107.8m

Price History & Performance

Summary of all time highs, changes and price drops for Iconovo
Historical stock prices
Current Share Price	SEK 5.12
52 Week High	SEK 12.55
52 Week Low	SEK 4.15
Beta	0.75
11 Month Change	0.39%
3 Month Change	-40.47%
1 Year Change	-44.83%
33 Year Change	-93.69%
5 Year Change	-91.74%
Change since IPO	-85.78%

Recent updates

Iconovo AB (publ)'s (STO:ICO) Intrinsic Value Is Potentially 37% Above Its Share Price

Jun 13

Companies Like Iconovo (STO:ICO) Can Afford To Invest In Growth

Apr 13

When Will Iconovo AB (publ) (STO:ICO) Turn A Profit?

Mar 18

Have Iconovo AB (publ) (STO:ICO) Insiders Been Selling Their Stock?

Feb 20

A Look At Iconovo's (STO:ICO) Share Price Returns

Feb 07

Have Insiders Been Buying Iconovo AB (publ) (STO:ICO) Shares?

Dec 21

Shareholder Returns

	ICO	SE Medical Equipment	SE Market
7D	-0.8%	-2.4%	-1.9%
1Y	-44.8%	-4.1%	12.5%

Return vs Industry: ICO underperformed the Swedish Medical Equipment industry which returned -3.9% over the past year.

Return vs Market: ICO underperformed the Swedish Market which returned 12.3% over the past year.

Price Volatility

Is ICO's price volatile compared to industry and market?
ICO volatility
ICO Average Weekly Movement	9.8%
Medical Equipment Industry Average Movement	7.4%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: ICO's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: ICO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

Founded	Employees	CEO	Website
2013	28	Johan Waborg	www.iconovo.se

Iconovo AB (publ) develops and licenses inhalation medications in Sweden. The company offers ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone Nasal single-dose dry powder inhaler for nasal use. It serves generic companies.

Iconovo AB (publ) Fundamentals Summary

How do Iconovo's earnings and revenue compare to its market cap?
ICO fundamental statistics
Market cap	SEK 81.50m
Earnings (TTM)	-SEK 40.20m
Revenue (TTM)	SEK 24.99m

3.3x

P/S Ratio

-2.0x

P/E Ratio

Is ICO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ICO income statement (TTM)
Revenue	SEK 24.99m
Cost of Revenue	SEK 6.44m
Gross Profit	SEK 18.55m
Other Expenses	SEK 58.75m
Earnings	-SEK 40.20m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 27, 2025

Earnings per share (EPS)	-2.53
Gross Margin	74.22%
Net Profit Margin	-160.91%
Debt/Equity Ratio	0%

How did ICO perform over the long term?

See historical performance and comparison

ICO Stock Overview

Rewards

Risk Analysis

Iconovo AB (publ) Competitors

OM:QLINEA

SEK 131.8m

OM:SDOS

SEK 92.9m

NGM:ODIN

SEK 59.9m

NGM:GTAB B

SEK 107.8m

Price History & Performance

Recent News & Updates

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2024 earnings released: kr0.70 loss per share (vs kr0.97 loss in 3Q 2023)

Iconovo Initiates Development of the GLP-1 Antibody Semaglutide in the Inhaler Iocone Nasal

New minor risk - Share price stability

Price target increased by 12% to kr23.50

Recent updates

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2024 earnings released: kr0.70 loss per share (vs kr0.97 loss in 3Q 2023)

Iconovo Initiates Development of the GLP-1 Antibody Semaglutide in the Inhaler Iocone Nasal

New minor risk - Share price stability

Price target increased by 12% to kr23.50

New major risk - Market cap size

Should You Investigate Iconovo AB (publ) (STO:ICO) At kr6.68?

Now 21% undervalued after recent price drop

Consensus revenue estimates increase by 17%

Iconovo AB (publ) Develops Intranasally Inhaled Semaglutide in ICOone Nasal for More User-Friendly Treatment of Overweight and Obesity

Vice President of Operations recently bought kr57k worth of stock

Second quarter 2024 earnings released: kr0.60 loss per share (vs kr1.32 loss in 2Q 2023)

Now 21% overvalued after recent price rise

Iconovo AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

Vice President of Operations recently bought kr80k worth of stock

Independent Director recently bought kr246k worth of stock

Now 22% overvalued after recent price rise

Iconovo AB (Publ) Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments

Consensus revenue estimates increase by 15%, EPS downgraded

New major risk - Shareholder dilution

Iconovo AB (publ) Receives Patent Protection for Icores in China

Iconovo AB (publ), Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: kr0.69 loss per share (vs kr1.35 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Iconovo AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 18.8 million.

Iconovo AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

New major risk - Market cap size

Insufficient new directors

New minor risk - Profitability

New major risk - Market cap size

Independent Chairman of the Board recently bought kr190k worth of stock

Third quarter 2023 earnings released: kr0.97 loss per share (vs kr1.14 loss in 3Q 2022)

Iconovo AB (publ) Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone

Iconovo AB (publ) Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations

Iconovo AB (Publ) Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027

New minor risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings released: kr1.36 loss per share (vs kr1.38 loss in 2Q 2022)

We're A Little Worried About Iconovo's (STO:ICO) Cash Burn Rate

Price target decreased by 27% to kr63.00

Iconovo AB (publ) Strengthens its Customer Offering in the Novel Pharmaceuticals Business Segment

Iconovo AB (Publ) Announces Appoints Carl Lindgren as Chief Business Development Officer

Independent Director recently sold kr98k worth of stock

Independent Director recently sold kr171k worth of stock

Chief Executive Officer recently bought kr61k worth of stock

Independent Chairman of the Board recently bought kr100k worth of stock

Iconovo AB (publ) to Report Fiscal Year 2022 Results on Feb 08, 2023

Insufficient new directors

Iconovo Receives Approval of New European Patent for Its Single-Use Inhaler ICOone®

Iconovo AB (publ) Announces Executive Changes, Effective April 1, 2023

Iconovo's ICOone Inhaler Platform Receives New Patent Approval in the US

Iconovo Announces Appointment of Nomination Committee

Third quarter 2022 earnings released: kr1.14 loss per share (vs kr0.43 loss in 3Q 2021)

Iconovo AB (publ) Conducts a User Study to Assess the Handling of its ICOone Nasal Inhaler

Here's Why We're Watching Iconovo's (STO:ICO) Cash Burn Situation

Second quarter 2022 earnings released: kr1.38 loss per share (vs kr0.85 loss in 2Q 2021)

Iconovo AB (Publ) Announces First Patent Grant in Japan for It's ICOone

Chief Executive Officer recently bought kr69k worth of stock